Closed · RFA-DE-19-004 · CFDA 93.121 · Discretionary

Encouraging Development of Novel Amelogenesis Models (UG3/UH3 Clinical Trial Not Allowed)

Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.

up to $400K
Award range
Closed
Status
October 4, 2018
Close date
-
Expected awards

The verdict

Encouraging Development of Novel Amelogenesis Models (UG3/UH3 Clinical Trial Not Allowed) is a closed discretionary listing from National Institutes of Health that offered Up to $400,000. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.

up to $400K
award range
Closed
application status
93.121
CFDA program
12,419
other opportunities from National Institutes of Health

Archived opportunity record

Encouraging Development of Novel Amelogenesis… is closed (last close October 4, 2018). The parent program page for CFDA 93.121 is the reliable place to catch re-announcements. National Institutes of Health still indexes 12,419 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed October 4, 2018

Posted Jul 11 Closes Oct 4

Est. Total Funding

$2,000,000

Instrument

Cooperative Agreement

Description

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to develop physiologically relevant models of amelogenesis that are robust and validated so that they can advance studies of healthy and diseased human conditions involving teeth. The objectives of this FOA are two-fold: 1) generate new and improved models that closely mimic physiological enamel development and maturation to empower studies of amelogenesis, and 2) validate those models to ensure they are robust and accurately reflect human physiology and pathology. These tandem objectives will be accomplished with an Exploratory/Developmental Phased Award Cooperative Agreement (UG3/UH3) mechanism, where the UG3 developmental phase is initiated and carried out through a milestone-driven process which will then be assessed to determine if advancement to the UH3 phase providing subsequent support to further advance the UG3 outcomes will be granted . It is expected this FOA will enhance the capability of resources to serve biomedical research and accelerate understanding of multiscale processes of enamel formation to inform strategies to mitigate diseases affecting enamel and associated structures.

Wide-open applicant board · 15 Grants.gov doors

Encouraging Development of Novel Amelogenesis… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity code maps to Health (HL). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).

Code 00
State governments
Code 01
County governments
Code 02
City or township governments
Code 04
Special district governments
Code 05
Independent school districts
Code 06
Public / state-controlled institutions of higher education
Code 07
Federally recognized tribal governments
Code 08
Public / Indian housing authorities
Code 11
Native American tribal organizations (other than Federally recognized tribal governments)
Code 12
Nonprofits with 501(c)(3) status (other than IHEs)
Code 13
Nonprofits without 501(c)(3) status (other than IHEs)
Code 20
Private institutions of higher education
Code 22
For-profit organizations other than small businesses
Code 23
Small businesses
Code 25
Others (see official listing text)

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

NIH OER Webmaster FBOWebmaster@OD.NIH.GOV

What to do next

Encouraging Development of Novel Amelogenesis… is closed; use the parent program and agency catalog for the next funding cycle.

  • Parent CFDA 93.121 may publish future NOFOs under the same assistance listing. Open program
  • Oral Health Prevention and Education indexes 107 Grants.gov listings in this extract. Program profile
  • National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants